How Long Does the Final Stage of ALS Last?

The final stage of ALS typically lasts several months, though the range spans from weeks to well over a year depending on the person’s age, where symptoms began, how fast the disease has been progressing, and which life-sustaining interventions are in place. Under a widely used clinical staging system, the final stage begins when a person needs a feeding tube or non-invasive ventilation, which occurs at roughly 80% of the way through the total disease course. That remaining 20% unfolds very differently from person to person, shaped by biology, genetics, and the decisions families and care teams make along the way.

What Counts as the Final Stage

ALS does not come with universally agreed-upon “stages” the way some cancers do, but a staging system published in the journal Brain has become the most referenced framework in research. It defines milestones based on how many body regions are affected and when life-sustaining supports become necessary. Stage 1 is symptom onset in a single region. Stage 2 covers diagnosis and spread to a second region. Stage 3 marks involvement of a third region. Stage 4, the final stage, is reached when a person needs either a gastrostomy (a feeding tube placed through the abdomen) or non-invasive ventilation to assist breathing.

By analyzing patients who had died, the researchers found that these milestones occur at remarkably predictable proportions of total disease duration. Diagnosis happened at about 35% through the disease course, a second region was affected at roughly 38%, a third region at about 61%, and the need for gastrostomy or ventilation arrived at approximately 77–80%.¹ That means Stage 4 encompasses roughly the final fifth of the illness. For someone with a three-year total disease course, that translates to about seven or eight months. For someone who lives five years from first symptoms, the final stage could stretch past a year.

The order of Stage 4 milestones also varies by onset type. People with bulbar-onset ALS, where the disease first affects speech and swallowing, tended to need a feeding tube before ventilation. Those with limb-onset ALS experienced the reverse, needing breathing support before a feeding tube.²

Why the Range Is So Wide

Quoting a single number for the final stage’s duration would be misleading because ALS is one of the most variable neurological diseases. Several factors reliably push the timeline shorter or longer.

Age at onset is among the strongest predictors. A population-based study found that people older than 75 at diagnosis faced roughly seven and a half times the death risk of younger patients.³ Older patients tend to move through every stage faster, including the last one.

Site of onset matters too. Bulbar-onset ALS, which begins with speech or swallowing difficulty, is consistently associated with shorter survival than limb-onset disease. A large meta-analysis identified bulbar onset as one of the strongest negative prognostic factors, alongside older age, rapid early decline on functional scales, and the presence of frontotemporal dementia.⁴ An Italian population-based study confirmed that age at onset, site of onset, and the rate of functional decline at diagnosis independently influenced survival.⁵

The rate of progression itself is not constant. Research has shown that functional decline in ALS is non-linear, with the fastest deterioration occurring in the early and late phases of the illness.⁶ That late-phase acceleration is part of what makes the final stage feel so abrupt to families, even when it lasts months on paper.

The Role of Genetics

About 5–10% of ALS cases are familial, meaning they are linked to a known genetic mutation. The specific gene involved can dramatically alter how long the final stage lasts.

Patients carrying SOD1 mutations tend to have much slower disease progression. One study found their median survival from onset was about 198 months, with a functional decline rate of roughly 0.2 points per month on the standard ALS rating scale.⁷ By contrast, people with C9orf72 mutations, the most common genetic cause of ALS, progressed faster and reached death or tracheostomy earlier, with a median of about 31 months compared to 37 months in non-carriers.⁸ A separate study looking at the extremes of the survival spectrum found that C9orf72 expansions appeared only in fast progressors, while SOD1 variants were found in both fast and slow groups.⁹

Most people with ALS don’t have an identified genetic cause, so these numbers won’t apply directly to them. But the genetic findings illustrate just how much the disease’s timeline can vary, even within the same diagnostic label.

How Ventilation Changes the Timeline

Because respiratory failure is the usual cause of death in ALS, decisions about breathing support have the single largest effect on how long the final stage lasts. There are two main forms: non-invasive ventilation (NIV), delivered through a mask, and tracheostomy invasive ventilation (TIV), which requires a surgically placed tube in the windpipe.

NIV, when used consistently, is associated with a meaningful survival benefit. A large study matching NIV users with non-users found that NIV was linked to a roughly 26% reduction in the rate of death overall, and a 37% reduction among people with limb-onset ALS. Using NIV for at least four hours per day was associated with improved survival.¹⁰

TIV extends survival considerably further. A German cohort study found median survival of about 82 months with TIV, compared to roughly 41 months with NIV and about 34 months without any ventilation.¹¹ Japanese data showed similar patterns, with TIV yielding a median of 74 months, NIV about 48 months, and no ventilation about 32 months.¹² An Italian study found tracheostomy increased median survival from 31 to 47 months, with the greatest effect in people younger than 60.¹³

TIV is a complex choice. It can extend life by years, but it also means full dependence on a ventilator, usually round-the-clock nursing care, and eventual loss of the ability to speak or move. Rates of TIV use vary enormously by country and culture, with Japan having historically much higher uptake than most Western countries.

Riluzole’s Specific Effect on Stage 4

Riluzole, the first drug approved for ALS, has a modest overall survival benefit. A large multi-center study found that treated patients had about seven months longer median survival than untreated patients, though the benefit was most pronounced in people who were progressing fastest.¹⁴

What is particularly relevant to the final stage question is where riluzole’s benefit concentrates. A retrospective analysis of clinical trial data found that riluzole at the standard dose significantly lengthened time spent in Stage 4 specifically, with treated patients roughly 45% less likely to die while in that stage compared to those on placebo. The drug did not appear to slow progression through the earlier stages.¹⁵ In practical terms, riluzole may add weeks to months in the final stage rather than delaying arrival there.

What the Final Stage Looks and Feels Like

Understanding duration matters less to most families than understanding what to expect day to day. Research on the final weeks paints a fairly consistent picture.

A caregiver survey found that the most common symptoms in the last month of life were difficulty communicating (reported for about 62% of patients), shortness of breath (56%), discomfort other than pain (48%), and insomnia (42%). Pain was both frequent and severe.¹⁶ A scoping review of the dying phase in motor neuron disease identified breathlessness, anxiety, and pain as the most common symptoms associated with approaching death, with worsening respiratory function and the development of new symptoms signaling that death was near.¹⁷

A Swedish study tracking patients during their final year found a slow decline in weight and motor function over 12 months, followed by an acceleration in the last days. In the final week, about 41% experienced at least one symptom, whether pain, anxiety, confusion, or breathlessness, that was only partially relieved or not relieved at all.¹⁸ That statistic is worth dwelling on: while many patients die peacefully with good symptom management, a substantial minority have symptoms that are difficult to fully control, which makes aggressive palliative care planning essential.

Nutrition and Body Weight in Late-Stage Disease

Weight loss is common throughout ALS, driven by swallowing difficulty, increased energy expenditure, and muscle wasting. In the final stage, nutritional status becomes a direct survival factor. One study found that underweight patients who received a feeding tube had more than three times the death risk of normal-weight patients.¹⁹ Research on gastrostomy-fed ALS patients confirmed that arm muscle measurements, as a marker of nutritional reserve, independently predicted how long a person survived on tube feeding, with each additional centimeter of muscle lowering death risk by about 10–11%.²⁰

An earlier study found that gastrostomy improved survival particularly after the first six months of tube feeding, and enhanced quality of life and social integration regardless of age.²¹ The practical implication is that feeding tube placement ideally happens before someone becomes severely malnourished, because the benefit is greatest when body reserves are still intact.

Hospice and Palliative Care Timing

Many ALS patients in the final stage transition to hospice care, though the timing varies widely. One U.S. study found that patients who enrolled in hospice stayed for a median of 84 days, with bulbar-onset patients trending toward shorter stays (about 71 days) and limb-onset patients staying somewhat longer (about 101 days). Patients who continued using NIV during hospice had similar lengths of stay as those on no respiratory support, suggesting that breathing assistance doesn’t necessarily delay hospice enrollment or compress the hospice period.²²

Specialty palliative care, when introduced earlier in the disease, appears to improve end-of-life planning without changing overall disease duration. A study comparing ALS patients who received specialty palliative care with those who received standard care found that the palliative care group had higher hospice enrollment, more frequent documentation of goals-of-care conversations, and better designation of healthcare proxies. Disease duration from the initial neuromuscular clinic visit to death was similar between groups.²³ Goals-of-care conversations occurred in the overwhelming majority of patients who received specialty palliative care, but in fewer than half of those who did not.

The Burden on Caregivers in the Final Stage

The final stage of ALS is arguably harder on families than on anyone else. A study interviewing former caregivers of deceased ALS patients found that 57% reported negative health outcomes related to their caregiving role, with the most common problems being difficulty obtaining medical aids (45%) and a lack of caregiver support (35%). Higher levels of reported deficits in the care system correlated with worse caregiver health and greater burden.²⁴ A mixed-methods study confirmed that the strongest predictors of caregiver burden were psychological distress, hours of care provided, and lower quality of life, with qualitative themes centering on the practical difficulties of managing ALS, emotional toll, and the restriction of the caregiver’s own life.²⁵

These findings point to something that pure survival statistics miss: the final stage’s duration matters not just medically but practically. A longer final stage with adequate support infrastructure can allow meaningful time for families. A longer final stage without adequate support can be devastating for caregivers’ physical and mental health.

Blood Biomarkers That Signal Faster Decline

Clinicians have been searching for blood-based markers that can tell families roughly where a patient is on the disease’s trajectory. Neurofilament proteins, released into the bloodstream when nerve cells are damaged, have emerged as the leading candidates. A meta-analysis found that ALS patients with the highest blood levels of neurofilament light chain had about four and a half times the death risk of those with the lowest levels, and that neurofilament levels correlated strongly with the rate of disease progression.²⁶ These markers are not yet used routinely to predict the exact length of the final stage, but they can help clinicians identify fast progressors early, which in turn informs decisions about when to start ventilation, place a feeding tube, or begin hospice conversations.

Survival Outliers and Plateaus

Not everyone follows the typical trajectory. A cohort study of long-term survivors found that they were younger at onset, more likely to be male, and more likely to have spinal-onset disease. About 75% of long-survivors had limb onset, compared to 59% of non-long-survivors.²⁷

Perhaps more surprising, a meaningful minority of ALS patients experience plateaus where functional decline stalls for months at a time. A population-based study of over 1,200 patients found that about one in six had at least one plateau lasting six months or more, and roughly one in 25 had a plateau of 18 months or longer. Plateaus were more common in people with spinal onset and those with a predominantly upper-motor-neuron pattern, and less common in older patients.²⁸ These plateaus tended to occur earlier in the disease course, but they underscore that ALS progression is not an unbroken downward slide for everyone.

When Ventilation Continues Indefinitely

For patients who opt for tracheostomy ventilation, the final stage as traditionally defined can extend for years, but it brings its own distinct challenges. A study of 70 ALS patients on tracheostomy ventilation found that about 11% had entered a totally locked-in state, meaning they had lost all voluntary movement including eye movements. Among those who had been on tracheostomy ventilation for more than five years, the rate rose to about 18%, with an additional 33% in a minimal communication state where only trace movements remained.²⁹

This raises difficult ethical questions. Brain-computer interfaces, which translate brain signals into text or cursor movement, are being explored as a way to maintain communication for people who have lost all other means. One case report documented an ALS patient who used an implanted brain-computer interface independently at home for seven years, gradually relying on it more as eye-tracking became unreliable, until eventually the brain interface itself lost reliability.³⁰ The technology is still in early stages, but it illustrates how the boundaries of the “final stage” are being reshaped by advances in assistive technology and life support.

For patients on long-term ventilation who later choose to withdraw, the dying process after disconnection varies depending on whether the person still has any ability to breathe independently. In one study, patients with some residual breathing capacity survived a mean of about 32 hours after ventilator withdrawal with symptom-focused sedation, while those with no independent breathing capacity died within minutes under continuous deep sedation.³¹ Both approaches kept patients comfortable, but the distinction matters for families preparing for what the final hours will look like.

When Cognitive Changes Overlap with ALS

About 15% of ALS patients also develop frontotemporal dementia (FTD), and a broader group experiences milder cognitive or behavioral changes. The overlap affects not just quality of life but survival itself. A study examining ALS-FTD phenotypes found that patients who presented with motor symptoms first had a median survival of about 2.7 years, significantly shorter than the 4.4 years seen in those whose cognitive symptoms came first.³² The large meta-analysis cited earlier identified comorbid FTD as one of the strongest negative prognostic factors, nearly tripling the risk of death.⁴

Cognitive involvement also complicates the final stage in ways that don’t show up in survival statistics. Patients with behavioral changes may resist interventions like NIV or feeding tubes, not out of informed preference but because of impaired judgment or apathy. This can compress the final stage in ways that feel avoidable to families, and it makes early advance-care planning even more critical for anyone with ALS who is showing signs of cognitive change.